BAM
LCTX icon

Belpointe Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Belpointe Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-611
Closed -$917 – 2118
2023
Q1 		$917 Hold
611
– – ﹤0.01% 3488
2022
Q4 		$715 Buy
+611
New +$770 ﹤0.01% 3494

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Belpointe Asset Management's LCTX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2023, closing a stake of 611 shares — an estimated $917 sold.

Belpointe Asset Management first reported a position in LCTX in Q4 2022 and held it in 2 quarters. The position peaked at $917 in Q1 2023. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Lineage Cell Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 611 Lineage Cell Therapeutics shares in Q2 2023, an estimated $917.
  • Belpointe Asset Management first reported a position in Lineage Cell Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Lineage Cell Therapeutics position peaked at $917 in Q1 2023.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.